PuO2 in RenalGuard Pilot Study
Launched by SAHLGRENSKA UNIVERSITY HOSPITAL · Mar 14, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥18 years of age
- • scheduled for cardiac surgery with normothermic CPB
- • Estimated glomerular filtration rate ≥50 ml/min as assessed by the CKD-EPI formula
- Exclusion Criteria:
- • Patient receiving furosemide at a dose\>100 mg/day orally (or the equivalent dose of an alternative loop diuretic) in the last week
- • Patient who cannot be urethrally catheterized for any reason
- • Patient already dialysis dependent
- • Known or suspected AKI (KDIGO criteria) at the time of screening
- • Any condition which, in the judgement of the investigator, might increase the risk to the patient
Trial Officials
Lukas Lannemyr Lannemyr, MD, PhD
Principal Investigator
Institute of Clinical Sciences, Dept of Anesthesia and Intensive Care, Sahlgrenska Academy, Gothenburg University. Gothenburg, Sweden
About Sahlgrenska University Hospital
Sahlgrenska University Hospital, a leading healthcare institution in Sweden, is at the forefront of clinical research and innovation. Affiliated with the University of Gothenburg, the hospital integrates advanced medical care with cutting-edge research, facilitating a collaborative environment for scientific exploration and clinical trials. With a commitment to improving patient outcomes, Sahlgrenska University Hospital focuses on a wide range of therapeutic areas, leveraging its multidisciplinary expertise to advance healthcare solutions. The institution is dedicated to fostering ethical research practices and ensuring the highest standards of patient safety and care in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported